Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Ruan, Qiurong; Yang, Kun; Wang, Wenxia; Jiang, Ling-Yu; Song, Jin Yeong

doi:10.1007/s00134-020-06028-z

Cited by 400 publications

(346 citation statements)

References 0 publications

Supporting

Mentioning

312

Contrasting

Unclassified

Order By: Relevance

“…Leucine-Rich Alpha-2-Glycoprotein LRG1 expression is induced by IL-6 (Shirai et al, 2009) , which is elevated in severe COVID-19 (Ruan et al, 2020) . LRG1 promotes angiogenesis (Wang et al, 2013) and has been reported to be associated with local inflammation (Naka and Fujimoto, 2018) .…”

Section: Supplementary Informationmentioning

confidence: 99%

See 1 more Smart Citation

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

Messner

Demichev

Wendisch

et al. 2020

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic is an unprecedented global challenge. Highly variable in its presentation, spread and clinical outcome, novel point-of-care diagnostic classifiers are urgently required. Here, we describe a set of COVID-19 clinical classifiers discovered using a newly designed low-cost high-throughput mass spectrometry-based platform. Introducing a new sample preparation pipeline coupled with short-gradient high-flow liquid chromatography and mass spectrometry, our methodology facilitates clinical implementation and increases sample throughput and quantification precision. Providing a rapid assessment of serum or plasma samples at scale, we report 27 biomarkers that distinguish mild and severe forms of COVID-19, of which some may have potential as therapeutic targets. These proteins highlight the role of complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling upstream and downstream of Interleukin 6. Application of novel methodologies hence transforms proteomics from a research tool into a rapid-response, clinically actionable technology adaptable to infectious outbreaks. Highlights-A completely redesigned clinical proteomics platform increases throughput and precision while reducing costs.-27 biomarkers are differentially expressed between WHO severity grades for COVID-19.-The study highlights potential therapeutic targets that include complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling both upstream and downstream of interleukin 6.

show abstract

Section: Supplementary Informationmentioning

confidence: 99%

“…Elevated in acute-phase response (Jain et al, 2011) . Of note, HP expression is known to be promoted by IL-6 , which is elevated in severe COVID-19 (Ruan et al, 2020) .…”

Section: Supplementary Informationmentioning

confidence: 99%

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

Messner

Demichev

Wendisch

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Elderly people and people who have underlying medical conditions are at higher risk for developing more serious complications, such as septic shock, ARDS, acute kidney injury (AKI), and fulminant myocarditis. 6,7 Approximately 81% of deaths occurred among people aged >60 years in China. 5 As a new infectious disease, COVID-19 is characterized by severe acute respiratory injury and hyperinflammation-related syndromes.…”

Section: Introductionmentioning

confidence: 99%

Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment

Li¹,

Zhang²,

Xiao³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Coronavirus infectious disease 2019 (COVID-19) has developed into a global pandemic. It is essential to investigate the clinical characteristics of COVID-19 and uncover potential risk factors for severe disease to reduce the overall mortality rate of COVID-19. Methods Sixty-one critical COVID-19 patients admitted to the intensive care unit (ICU) and 93 severe non-ICU patients at Huoshenshan Hospital (Wuhan, China) were included in this study. Medical records, including demographic, platelet counts, heparin-involved treatments, heparin-induced thrombocytopenia-(HIT) related laboratory tests, and fatal outcomes of COVID-19 patients were analyzed and compared between survivors and nonsurvivors. Findings Sixty-one critical COVID-19 patients treated in ICU included 15 survivors and 46 nonsurvivors. Forty-one percent of them (25/61) had severe thrombocytopenia, with a platelet count (PLT) less than 50x109/L, of whom 76% (19/25) had a platelet decrease of >50% compared to baseline; 96% of these patients (24/25) had a fatal outcome. Among the 46 nonsurvivors, 52.2% (24/46) had severe thrombocytopenia, compared to 6.7% (1/15) among survivors. Moreover, continuous renal replacement therapy (CRRT) could induce a significant decrease in PLT in 81.3% of critical CRRT patients (13/16), resulting in a fatal outcome. In addition, a high level of anti-heparin-PF4 antibodies, a marker of HIT, was observed in most ICU patients. Surprisingly, HIT occurred not only in patients with heparin exposure, such as CRRT, but also in heparin-naive patients, suggesting that spontaneous HIT may occur in COVID-19. Interpretation Anti-heparin-PF4 antibodies are induced in critical COVID-19 patients, resulting in a progressive platelet decrease. Exposure to a high dose of heparin may trigger further severe thrombocytopenia with a fatal outcome. An alternative anticoagulant other than heparin should be used to treat COVID-19 patients in critical condition.

show abstract

“…Although most cases are mild to moderate in severity, about 15% develop severe pneumonia, and nearly 5% progress to acute respiratory distress syndrome and multiple organ failure [25,49]. This worsening is predominantly driven by cytokine upregulation and an exaggerated yet maladaptive inflammatory response [35,40,47]. Direct viral infection and cytopathic effects may also play a role.…”

Section: Introductionmentioning

confidence: 99%

Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series

et al. 2020

View full text Add to dashboard Cite

There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 . Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients (n = 6; age range 19-75 years, 1 female) required ventilatory support (invasive mechanical ventilation, n = 5) with PaO 2 /FiO 2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43-2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89-1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26-0.82 × 10 3 / µl) but had increased in three of these five patients at last follow-up (range 0.23-1.02 × 10 3 /µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.

show abstract

Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Abstract: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cited by 400 publications

References 0 publications

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment

Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series

Contact Info

Product

Resources

About